Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0133 • ACR Convergence 2021
Cervical Cancer Screening Rate in Women with Systemic Lupus Erythematosus
Erica Rosen¹ and Megan Krause², ¹University of Kansas, Kansas City, MO, ²University of Kansas, Kansas City, KS
Background/Purpose: Females with systemic lupus erythematosus have increased rates of cervical cancer especially if on immunosuppressive therapy. The American Cancer Society reports the incidence of…
Abstract Number: 0332 • ACR Convergence 2021
Prevalence of Systemic Lupus Erythematosus in the United States: Updated Population Representative Estimates from the Medical Expenditure Panel Survey (MEPS) 2016-2018
Michael Pollack¹, Sandra Sze-jung Wu¹, Eilleen Farrelly², Shannon Grabich³ and Robert Ortmann⁴, ¹AstraZeneca, Wilmington, DE, ²Xcenda, Carrollton, TX, ³Xcenda, Durham, NC, ⁴AstraZeneca, Greenwood, IN
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multi-organ, autoimmune disease whose prevalence in the US has not been recently updated in real-world studies. Prevalence…
Abstract Number: 0349 • ACR Convergence 2021
Performance of the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Predominantly African American Cohort
Jessica English¹, Dulaney Wilson², Gary Gilkeson², Jim Oates² and Diane Kamen², ¹Medical University of South Carolina, Johns Island, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Classification criteria for systemic lupus erythematosus (SLE) were recently published by the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) to…
Abstract Number: 0534 • ACR Convergence 2021
Lymphatic Dysfunction in Murine Lupus Photosensitivity
William Ambler¹, Noa Schwartz², Jin Yeon Shin³, Rahgu Kataru⁴, Camila Carballo⁵, Scott Rodeo⁶, Babak Mehrara⁴ and Theresa Lu⁷, ¹Division of Pediatric Rheumatology, Department of Rheumatology, Hospital for Special Surgery. HSS Research Institute, Hospital for Special Surgery, New York, NY, ²Department of Medicine, Division of Rheumatology, Albert Einstein College of Medicine, New York, NY, ³Department of Surgery, Division of Plastic and Reconstructive Surgery Memorial Sloan Kettering, New York, NY, ⁴Department of Surgery, Division of Plastic and Reconstructive Surgery, Memorial Sloan Kettering, New York, NY, ⁵HSS Research Institute, Hospital for Special Surgery, New York, NY, ⁶HSS Research Institute, Hospital for Special Surgery; Department of Orthopedics, Hospital for Special Surgery, New York, NY, ⁷Hospital for Special Surgery, New York, NY
Background/Purpose: The lymphatic system is composed of vessels which carry fluid, soluble molecules, and cells from peripheral tissue to draining lymph nodes. Photosensitivity, an exaggerated…
Abstract Number: 0624 • ACR Convergence 2021
Validation of a Self-reported Measure of Extent and Reasons for Nonadherence in SLE
Kai Sun¹, Amanda Eudy², D. Ryan Anderson³, Rebecca Sadun², Lisa Criscione-Schreiber¹, Jayanth Doss², Jennifer Rogers¹, Theresa Coles², Corrine Volis⁴ and Megan Clowse⁵, ¹Duke University School of Medicine, Durham, NC, ²Duke University, Durham, NC, ³Duke University Medical Center, Durham, NC, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵Duke University, Chapel Hill, NC
Background/Purpose: Medication nonadherence is common in SLE and leads to increased hospitalizations, morbidity, and mortality. To better recognize nonadherence and address adherence barriers, there is…
Abstract Number: 0856 • ACR Convergence 2021
Identifying COVID-19 Infection Rates and Outcomes in Patients with Systemic Lupus Erythematosus
Alexander Hall¹, Michael Trevisonno¹, Elizabeth Murray¹, Omoakhe Tisor¹, Emily Stanford¹, Jacob Gaines¹, Noor Anvery¹ and Ellen Ginzler², ¹SUNY Downstate Health Sciences University College of Medicine, Brooklyn, NY, ²SUNY Downstate Health Sciences University, Brooklyn, NY
Background/Purpose: The risk of COVID-19 infection among patients with Systemic Lupus Erythematosus (SLE) is poorly understood. Patients with SLE often take medications which modulate the…
Abstract Number: 0873 • ACR Convergence 2021
Clinical and Serological Characteristics of Latin American Patients with Lupus Enteritis: A Case-Control Study
Marcela Muñoz-Urbano¹, Julian Sanchez-Bautista², Yeison Santamaria-Alza¹, Diana C. Quintero-González³, Andres Ramirez², Adriana Lucía Vanegas-García⁴, Gloria M. Vasquez¹ and Luis Alonso Gonzalez³, ¹Rheumatology section, Universidad de Antioquia, Medellín, Colombia, ²Department of internal medicine, Universidad de Antioquia, Medellín, Colombia, ³Division of rheumatology, Universidad de Antioquia, Medellín, Colombia, ⁴Division of rheumatology, Universidad de Antioquia – Hospital San Vicente Fundación, Medellín, Colombia
Background/Purpose: Lupus enteritis (LE) is a potentially life-threatening manifestation of systemic lupus erythematosus (SLE), with an incidence ranging from 8% to 27%. Timely diagnosis is…
Abstract Number: 0890 • ACR Convergence 2021
Depression Is Associated with Frailty in Systemic Lupus Erythematosus Patients: Multicenter Retrospective Analysis Using Systemic Lupus Erythematosus International Collaborating Clinics-Frailty Index
Kichul Shin¹, In Ah Choi², Eunyoung Lee³, SE RIM CHOI⁴, Jina Yeo⁵, Yun Jong Lee⁶, Su-Jin Yoo⁷, Bong-Jin Hahm⁴, Jee Eun Park⁴, Ju Ho Lee⁸, Yeong-Wook Song⁴ and Ju Yeon Kim⁴, ¹Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea, ²Chungbuk National University Hospital, Cheongju, Republic of Korea, ³Uijeongbu Eulji Medical Center, Seoul, South Korea, ⁴Seoul National University Hospital, Seoul, Republic of Korea, ⁵Gil Medical Center, Seoul, South Korea, ⁶Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea, ⁷Chungnam National University Hospital, Daejeon, Republic of Korea, ⁸Seoul National University Bundang Hospital, Yongin Si, Republic of Korea
Background/Purpose: Systemic Lupus Erythematosus International Collaborating Clinics-Frailty Index (SLICC-FI) is a novel health measure in systemic lupus erythematosus (SLE) and was reported to have impact…
Abstract Number: 1029 • ACR Convergence 2021
Evaluation of the EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Population-Based Registry
Allison Guttmann¹, Brendan Denvir¹, Jill Buyon², Martin Aringer³, H. Michael Belmont², Sara Sahl⁴, Jane Salmon⁵, Anca Askanase⁶, Joan Bathon⁷, Laura Geraldino⁸, Yousaf Ali⁹, Ellen Ginzler¹⁰, Chaim Putterman¹¹, Caroline Gordon¹², Charles Helmick¹³, Hilary Parton¹⁴ and Peter Izmirly¹, ¹New York University School of Medicine, New York, NY, ²NYU School of Medicine, New York, NY, ³Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, ⁴UCLA-Harbor, Los Angeles, CA, ⁵Hospital for Special Surgery, New York, NY, ⁶Columbia University Medical Center, New York, NY, ⁷Columbia University, New York, NY, ⁸New York Presbyterian Hospital - Columbia Campus, New York, NY, ⁹Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰SUNY Downstate Health Sciences University, Brooklyn, NY, ¹¹Albert Einstein College of Medicine, Bronx, NY, ¹²Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ¹³Centers for Disease Control and Prevention, Atlanta, GA, ¹⁴New York City Department of Health and Mental Hygiene, Long Island City, NY
Background/Purpose: The Manhattan Lupus Surveillance Program (MLSP) is a multi-racial/ethnic population-based registry with the primary goal to determine the prevalence and incidence of Systemic Lupus…
Abstract Number: 1163 • ACR Convergence 2021
Patients’ Insights About Hydroxychloroquine, and Patient-Recommended Strategies to Target Nonadherence
Shivani Garg¹, Betty Chewning¹, Noah Kaitz¹, Shelby Gomez¹ and Christie Bartels², ¹UW Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) is the cornerstone of SLE therapy as it improves damage-free survival in all SLE patients. Yet, in new users, as few as…
Abstract Number: 1270 • ACR Convergence 2021
Disease Severity and Healthcare Costs Associated with Chronic Kidney Disease in Patients with Systemic Lupus Erythematosus
Shirley Huang¹, Amy Guisinger², Carlyne Averell¹ and Christopher Bell¹, ¹GlaxoSmithKline, Research Triangle Park, NC, ²US Value, Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE), occurring in approximately 40% of SLE patients (pts) and often resulting in…
Abstract Number: 1286 • ACR Convergence 2021
Twenty-Year Trends in Systemic Lupus Erythematosus All–Cause Mortality in Mexico: A Nationwide Health Registry
Claudia Mendoza-Pinto¹, Ivet Etchegaray-Morales², Mario García-Carrasco², Pamela Munguía-Realpozo² and Socorro Méndez-Martínez³, ¹Instituto Mexicano del Seguro Social, San Andres Cholula, Mexico, ²Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, ³Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: Marked regional variation in systemic lupus erythematosus (SLE) mortality may be due to different spectra of local environmental factors. There have been no large…
Abstract Number: 1303 • ACR Convergence 2021
Associations Between Early Changes in Circulating B Cell Subsets and Severe Flare in Systemic Lupus Erythematosus – Results from Three Phase III Trials of Belimumab
Ioannis Parodis¹, Alvaro Gomez², Julius Lindblom², Alexander Borg², Sharzad Emamikia² and Mariele gatto³, ¹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden and Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, ²Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Department of Rheumatology, University of Padua, Padua, Italy
Background/Purpose: Belimumab is the only approved targeted treatment for systemic lupus erythematosus (SLE). Identification of early predictors of response or non-response to therapy is imperative…
Abstract Number: 1464 • ACR Convergence 2021
Ambulatory Fetal Heart Rate Monitoring (FHRM) to Surveil Pregnancies at Risk for Congenital Heart Block
Mala Masson¹, Colin Phoon¹, Elena Sinkovskaya², Lisa Howley³, Ruben Acherman⁴, Majd Makhoul⁵, Nelangi Pinto⁶, Miao Chang¹, Robert Clancy⁷, Bailey Drewes⁸, Bettina Cuneo⁹ and Jill Buyon⁷, ¹NYU Langone Health, New York, NY, ²East Virginia Medical School, Norfolk, ³Children's Hospitals and Clinics of Minnesota, Minneapolis, MN, ⁴Sunrise Children's Hospital, Las Vegas, NV, ⁵UK Kentucky Children's Hospital, Lexington, KY, ⁶University of Utah, Salt Lake City, UT, ⁷NYU Grossman School of Medicine, New York, NY, ⁸CU Anschutz Medical Campus, Aurora, ⁹Children's Hospital Colorado, Aurora, CO
Background/Purpose: Congenital Heart Block (CHB) complicates 2% of anti-Ro/SSA antibody positive pregnancies and carries substantial perinatal morbidity and mortality. Almost all survivors require lifelong pacing.…
Abstract Number: 1497 • ACR Convergence 2021
Kidney Disease in Lupus Patients Is Linked to Monocytes’ Aberrant Spliceosome and Altered Expression of IFN-Response Related Genes
Chary Lopez-Pedrera¹, Alejandra Patiño-Trives², Alejandro Ibañez-Costa³, Maria Luque-Tevar², Iván Arias de la Rosa⁴, Desiree Ruiz⁵, Pedro Seguí-Azpilicueta⁵, Mario Espinosa⁵, Rosa Ortega⁵, Nuria Barbarroja⁴, Justo P Cataño³, Raul Luque³, Maria Angeles Aguirre¹ and Carlos Pérez-Sánchez⁶, ¹IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ²Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, ³IMIBIC, Department of Cell Biology, Physiology and Immunology, University of Cordoba, Córdoba, Spain, ⁴University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁵IMIBIC, Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ⁶IMIBIC, Córdoba, Spain
Background/Purpose: The present study aimed at: 1- Identifying altered SLE monocytes transcriptomic signatures linked to the immune response and its association with clinical features. 2-…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].